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Background: The prognosis for renal cell carcinoma (RCC) is related to a high rate of metastasis, including 30% of
bone metastasis. Characteristic for bone tissue is a high concentration of calcium ions. In this study, we show a
promoting effect of an enhanced extracellular calcium concentration on mechanisms of bone metastasis via the
calcium-sensing receptor (CaSR) and its downstream signaling molecules.
Methods: Our analyses were performed using 33 (11/category) matched specimens of normal and tumor tissue
and 9 (3/category) primary cells derived from RCC patients of the 3 categories: non-metastasized, metastasized into
the lung and metastasized into bones during a five-year period after nephrectomy. Expression of CaSR was
determined by RT-PCR, Western blot analyses and flow cytometry, respectively. Cells were treated by calcium and
the CaSR inhibitor NPS 2143. Cell migration was measured in a Boyden chamber with calcium (10 μM) as
chemotaxin and proliferation by BrdU incorporation. The activity of intracellular signaling mediators was quantified
by a phospho-kinase array and Western blot.
Results: The expression of CaSR was highest in specimens and cells of patients with bone metastases. Calcium
treatment induced an increased migration (19-fold) and proliferation (2.3-fold) exclusively in RCC cells from patients
with bone metastases. The CaSR inhibitor NPS 2143 elucidated the role of CaSR on the calcium-dependent effects.
After treatment with calcium, the activity of AKT, PLCγ-1, p38α and JNK was clearly enhanced and PTEN expression
was almost completely abolished in bone metastasizing RCC cells.
Conclusions: Our results indicate a promoting effect of extracellular calcium on cell migration and proliferation of
bone metastasizing RCC cells via highly expressed CaSR and its downstream signaling pathways. Consequently,
CaSR may be regarded as a new prognostic marker predicting RCC bone metastasis.
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Approximately 30% of patients with renal cell carcinoma
(RCC) develop bone metastases during the course of the
disease. The median survival of patients presenting with
bone metastases at the time of RCC diagnosis is
10.6 months [1]. Bone metastases from RCC are* Correspondence: brenner@uni-mainz.de
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reproduction in any medium, provided the ordestructive and cause osteolysis. The consequences are
skeletal complications such as bone pain, pathologic
fractures, hypercalcaemia and spinal cord and nerve root
compression [2,3]. The prognosis for patients is poor be-
cause RCC bone metastases are practically insensitive to
standard therapy, such as conventional radiation or
chemotherapy [4,5].
The formation of metastases is a process involving
multiple steps. First, tumor cells escape from the pri-
mary tumor and migrate towards the blood vessels. After
dissemination by the blood flow they become trapped in
small capillaries in the secondary organ. The tumor cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the capillary walls into the subendothelial tissue [6,7].
The formation of metastases depends on the microenvir-
onment of the secondary organ being compatible to the
invading tumor cell [8]. The organ specificity of metasta-
sis can be caused by a particular constitution of the
endothelium, for example bone marrow sinusoid capil-
laries being highly fenestrated [9] and/or the chemotacti-
cal behavior and tumor growth promoting effect of the
subendothelial tissue, including the composition of
extracellular matrix compounds and growth factors [10].
The high frequency of bone metastases deriving from
RCC indicates an environment in this organ with the
ability to promote renal tumor cells with supporting
processes such as cell motility, adhesive interactions, cell
proliferation and tumor growth. Bone remodeling is a
physiological process of permanent bone resorption by
osteoclasts and bone formation by osteoblasts. During
this process calcium ions are released into the bone
matrix in high concentrations [3,11].
The impact of extracellular calcium on cells implicates
an activation of the calcium-sensing receptor (CaSR), a
G-protein-coupled receptor [12]. It is highly expressed
in the healthy kidney [13] and governs several functions:
regulation of extracellular calcium concentration and in-
organic phosphate homeostasis, mono- and divalent cat-
ion transport, acidification and concentration of urine as
well as renin release [14-16]. When activated through
enhanced extracellular calcium concentration, CaSR co-
ordinates cellular responses via a variety of intracellular
signaling pathways. These finally lead to a modulation of
cell proliferation, differentiation, migration and apop-
tosis [17]. In breast cancer, the expression of CaSR cor-
relates with the formation of bone metastases [18].
Since CaSR is highly expressed in epithelial cells of the
healthy kidney, we also assume a relatively high expres-
sion of this receptor in renal tumor cells and a promot-
ing effect of calcium on bone metastatic processes,
which has not been studied in detail. In this study we in-
vestigated the oncogenic properties of CaSR in RCC and
the influence of extracellular calcium on the formation
of RCC bone metastases. We correlated CaSR mRNA
expression in primary RCC tissue samples with the
localization of metastases. Additionally, the expression
of CaSR was analyzed in primary RCC cells of patients
with different metastatic localizations. To study the ef-
fect of extracellular calcium on metastatic behavior, we
quantified the chemotactical migration and cell prolifer-
ation of these RCC cells under calcium influence. The
molecular mechanisms responsible for the effects ob-
served were analyzed by quantifying the activity of intra-
cellular signaling pathways, especially the AKT and
MAPK pathways and its regulatory phosphatase PTEN.
The elucidation of the importance of calcium and CaSRin the process of bone metastasis could reveal new prog-
nostic markers and contribute to the development of
new target therapies.
Results
Tissue specimens of RCC patients developing bone
metastases show a high CaSR expression
Quantification of the CaSR expression in RCC was per-
formed by analyzing tumor and normal tissue specimens
from RCC patients without metastases and from patients
developing lung or bone metastases within 5 years after
nephrectomy (11 patients/category) by quantitative RT-
PCR. The results were correlated with the localization of
the metastatic sites. In tumor specimens of patients devel-
oping bone metastases, CaSR mRNA expression was 7.9-
fold higher than in tumor specimens of patients without
metastases (Figure 1A). Tumor specimens from patients
with no metastases or with lung metastases expressed
CaSR mRNA moderately. In normal renal tissue, CaSR ex-
pression was considerably higher than in tumor speci-
mens. In normal renal tissue of patients developing bone
metastases, CaSR mRNA expression was 1.8-fold higher
than in specimens of patients without metastases
(Figure 1B). Analyzing the CaSR protein in the tissue
specimens we observed a similar trend, although the effect
was even less pronounced (Figure 1C and D).
Bone metastatic primary RCC cells show a high CaSR
expression
The expression of CaSR in primary RCC cells was deter-
mined by flow cytometry. Corresponding to the results
obtained from tissue specimens, CaSR expression in
RCC cells cultivated from patients developing bone me-
tastases was 3.7-fold higher than in cells from patients
without metastases (p = 0.006). In cells from patients de-
veloping lung metastases, CaSR expression was 1.9-fold
higher than in non-metastasizing RCC cells. Treatment
with 5 mM calcium had no influence on CaSR expres-
sion of RCC cells (Figure 2).
Extracellular calcium stimulates migration and
proliferation of bone metastasizing primary RCC cells
Since the CaSR expression was enhanced in tumor tissue
and primary cells from patients who developed bone me-
tastases, we investigated the influence of extracellular cal-
cium in processes of metastasis. The migratory potential
of primary RCC cells was analyzed in a Boyden chemo-
taxis chamber using calcium as chemotaxin. To investi-
gate the influence of calcium on proliferation of these
primary RCC cells, they were incubated with calcium for
30 min and cell proliferation was determined by BrdU in-
corporation. The migratory potential of RCC cells from
patients with bone metastases was clearly increased (19-


















































































































Figure 1 CaSR expression in renal tissue specimens of RCC
patients with varying metastatic sites. Total RNA was isolated
and reverse transcribed from renal tumor (A) and normal kidney
(B) tissue specimens from 33 patients with RCC developing no
metastases, lung or bone metastases within 5 years after
nephrectomy (11/category). CaSR mRNA was quantified by real time
PCR. Real time PCR of TBP was performed simultaneously for
reference. Values are demonstrated as relative units (rel. u.) CaSR was
highly expressed in normal kidney tissue and in renal tumor tissue
of patients who developed bone metastases within 5 years after
nephrectomy. In renal tumor tissue of patients with no or with lung
metastases almost no CaSR was detectable. From the same tissue
specimens protein was extracted and CaSR was quantified by
Western blot. A similar trend was observed, although the effect was
even less pronounced (C and D). Box plots show medians (central
lane), 25% and 75% percentiles (lower and upper side of the box)
and minimum and maximum (lower and upper bars). Outliers are
not shown.
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gratory potential than non-metastasizing cells (3.8-fold).
Thus, in contrast to metastasizing cells, non-metastasizing
cells were only slightly responsive to calcium as a chemo-
taxin (Figure 3A). Furthermore, in bone metastatic RCC
cells extracellular calcium increased proliferation in aconcentration-dependent manner up to 2.3-fold. RCC
cells from patients with no metastases or with lung metas-
tases were not influenced by elevated calcium concentra-
tions (Figure 3B). Using the allosteric CaSR inhibitor NPS
2143, bone metastatic RCC cells were no longer respon-
sive to calcium (cell migration: p = 0.078, proliferation p =
0.154), which confirmed the effect of calcium via the CaSR
(Figure 3A, B). These results show that elevated extracel-
lular calcium promotes CaSR dependent migration and
proliferation of primary RCC cells with a high potential
for building skeletal metastases.Extracellular calcium enhances the activity of AKT, PLCγ-1,
JNK, p38α, paxillin and reduces the expression of PTEN
To analyze the signaling pathways involved in the
calcium-dependent effects demonstrated in this study, we
performed a human phospho-kinase array including 46
intracellular kinases. The activity of the kinases was mea-
sured by detecting the expression of the phosphorylated
molecules. In bone metastasizing cells, the following mol-
ecules showed a prominently enhanced phosphorylation
status due to their activation by calcium treatment
(Figure 4A): AKT (phosphorylation site Ser473: increase
of 165%, phosphorylation site Thr308: increase of 43%),
PLCγ-1 (increase of 35%), p38α (increase of 53%), JNK
(increase of 33%) and paxillin (increase of 39%). In case of
NPS 2143 treatment 30 min before adding Calcium, these
effects were inhibited. The expression of AKT Ser473 was
clearly reduced when cells were NPS 2143 treated. In con-
trast, ERK was not influenced after calcium treatment of
the bone metastasizing cells (data not shown). In non-
metastasizing cells, calcium had no activating effect on the
analyzed kinases (Figure 4A). Since these kinases are
members of the AKT signaling pathway and because the
AKT and ERK pathways are mainly activated by CaSR,
these results were substantiated by Western blot analysis
of phosphorylated AKT and ERK. The results corre-
sponded to those obtained by the human phospho-kinase
array (Figure 4B). PTEN expression was markedly reduced
in bone metastatic cells to 55%. Calcium treatment re-
sulted in significantly (p < 0.05) reduced PTEN expression
in all cell types, in bone metastasizing cells it was almost
undetectable (Figure 5).Discussion
Although a number of described mechanisms are impli-
cated in the process of cancer metastasis, the organ-
selective nature of cancer cells remains poorly understood.
The microenvironment of metastatic sites is apparently
crucial in several respects e.g. chemotactical power leading
tumor cells to a directive migration and a proliferation
supporting composition [6-8,19]. This aspect is more im-










































Figure 2 CaSR expression in primary RCC cells of different metastatic potential. CaSR expression was quantified in primary RCC cells of 9
patients developing no metastases, lung or bone metastases within 5 years after nephrectomy (3/category) after treatment with 5 mM calcium
for 30 min by flow cytometry. Exemplarily demonstrated in the histograms are IgG control (gray line) and calcium treated cells (black line). CaSR
expression was highest in patients with bone metastases, p = 0.006. Treatment with calcium (5 mM) had no effect on CaSR expression. The
columns represent mean values of 10.000 counted cells and standard error in% of values of non-metastasizing tumor cells (= cells of patients
without metastases). An isotype specific IgG control antibody was used for control.
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plies a weak barrier for tumor cells [9,20].
The inimitable microenvironment in bones implicates
a high concentration of calcium since calcium ions are
released in the bone matrix in high concentrations dur-
ing bone turnover [3,21]. Cells have the ability to
recognize extracellular calcium by CaSR [12], which in
some cancer entities, such as breast cancer, correlates
with bone metastasis [18]. In healthy breast tissue, CaSR
is responsible for the regulation of calcium concentra-
tion in milk and is therefore highly expressed [22].
Healthy kidney tissue also expresses CaSR as a regulator
for the resorption of calcium from primary urine [14].
As in breast cancer, renal cancer has a high potential of
metastasizing into bones [1], indicating a cancer cell
promoting environment in this organ. We investigated
the importance of high extracellular calcium concentra-
tions in the determination of bone specificity of RCC
metastasis. We analyzed the influence of calcium on cel-
lular behavior and investigated the role of CaSR in pro-
cesses of metastasis. In tumor tissue specimens of RCC
patients with bone metastases during 5 years after neph-
rectomy, we found a distinctly higher expression ofCaSR, compared to tumor tissue specimens of patients
with no or with lung metastases. This finding implicates
the participation of calcium and CaSR in bone metasta-
sis in RCC, which is already constituted in the primary
tumor. Interestingly, in the corresponding normal renal
tissue of patients with bone metastases, CaSR expression
was also higher than in the tissue of patients with no or
with lung metastases. Therefore the disposition for bone
metastasis is possibly already determined in healthy tis-
sue, or alternatively, the primary tumor induces en-
hanced CaSR in normal renal tissue. These results
indicate CaSR being a prognostic marker for the forma-
tion of bone metastases in RCC, as also postulated in
breast cancer [23,24].
The expression level of CaSR in primary RCC cells
showed a pattern similar to that found in tumor tissue.
CaSR expression was much higher in cells with a high
bone metastatic potential and lower in cells with lung
metastatic potential as compared to non-metastasizing
cells. In contrast to the expression of CaSR protein in
tumor specimens with a 1.5-fold higher value (median)
in patients with bone metastases compared to those
















































































5     mM
p = 0.099
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Figure 3 Calcium dependent cell migration and proliferation of
RCC cells of different metastatic potential. A, migration of
primary RCC cells of 9 patients developing no metastases, lung or
bone metastases within 5 years after nephrectomy (3/category) was
determined in a Boyden chemotaxis chamber using calcium
(10 mM) as chemotactic agent. Migration of RCC cells from patients
with bone metastases was clearly increased, p = 0.036. The columns
represent mean values and standard error in% of values from
non-metastasizing cells (= without metastases). B, primary RCC cells
of 9 patients developing no metastases, lung or bone metastases
within 5 years after nephrectomy (3/category) were treated with
calcium of different concentrations for 30 min. Proliferation of cells
from patients with bone metastases, determined by BrdU
incorporation, was increased after treatment with calcium, p = 0.099.
The columns represent mean values and standard error in% of
untreated cells. A, B, using the allosteric CaSR inhibitor NPS 2143
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β
Figure 4 Activity of intracellular kinases in primary RCC cells of
different metastatic potential after calcium treatment. (A)
Activity of AKT, p38α, JNK, paxillin and PLCγ-1 was analyzed by
measuring the phosphorylation status in primary RCC cells of
patients developing no metastases or bone metastases within 5 years
after nephrectomy via a human phospho-kinase array. Values of
calcium treated cells (5 mM, 30 min) with or without pretreatment
with NPS 2143 were related to untreated cells. The activity of AKT,
PLCγ-1, p38α, JNK and paxillin was increased in bone metastasizing
cells after treatment with calcium. This effect was inhibited using
NPS 2143. The columns represent the amount of antigen
determined by computer-aided integration of the bands after
subtraction of the background. Demonstrated are the mean values
of each lysate in% of untreated non-metastasizing cells (= without
metastases). (B) Western blot analysis of phosphorylated AKT and
ERK in cell lysates of untreated, calcium treated (5 mM, 30 min) or
NPS 2143 (5 μM, 30 min) following by NPS 2143 + calcium (30 min)
treated cells, 100 μg per lane. β-actin served as an internal control.
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This discrepancy may be caused by the fact, that FACS
analyses solely detect the biological active CaSR on the
cell surface, whereas an analysis of CaSR from a whole
protein extract of tissue also detects CaSR additionally
stored in vesicles of the cells. The similar tendency in

























Figure 5 Expression of PTEN in primary RCC cells of different
metastatic potential after treatment with calcium. Expression of
PTEN in primary RCC cells of patients developing no metastases or
bone metastases within 5 years after nephrectomy (3/category) was
analyzed by Western blotting after treatment with 5 mM calcium for
30 min or without treatment. β-actin was used as a loading control.
The expression of PTEN was lower in bone metastasizing cells and
further diminished after treatment with calcium. *1 p = 0.025,
*2 p = 0.009. The columns represent the amount of antigen
determined by computer-aided integration of the bands after
subtraction of the background and referred to the value of β-actin.
Demonstrated are the mean values in% of untreated non-
metastasizing cells (= without metastases) and the standard error.
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advocates further investigation in vitro using primary
cells. Treatment of RCC cells with calcium had no influ-
ence on the expression of CaSR, indicating that calcium
can be excluded as a regulator for the expression of
CaSR. These results confirm the hypothesis of Rogers
et al., who stated that calcium does not regulate the ex-
pression of CaSR due to the fact that calcium injected
into the inferior vena cava of rats did not significantly
change the CaSR expression in the parathyroid gland or
in the kidney [25].
Critical steps in metastasis are the migration of tumor
cells and cell proliferation in the secondary organ. In this
study the influence of calcium on these two steps was
analyzed in order to imitate the calcium conditions in
the bone microenvironment. In RCC cells metastasizing
into bones and expressing a high level of CaSR, the che-
motactical potential of calcium was 19-fold higher than
in non-metastasizing cells. The CaSR inhibitor NPS
2143 rescinded this effect, evidencing the importance of
CaSR in the calcium-dependent reaction. In lung metas-
tasizing RCC cells, calcium-dependent migration wasnearly the same as in non-metastasizing cells. This indi-
cates a CaSR-dependent chemotactical attraction of cal-
cium in bones inducing bone metastasis of RCC. Also
cell proliferation of bone metastasizing RCC cells, in
contrast to non- or lung metastasizing cells, was highly
sensitive to calcium, dependent on CaSR. These results
indicate a calcium dependence of bone metastasis in
RCC, as already defined in the primary tumor by CaSR
expression. Since RCC metastasis shows an osteolytic
property [2] after initiating bone metastasis, the calcium
concentration rises due to bone resorption, which in
turn leads to an additional increase of the metastatic po-
tential of RCC cells.
CaSR seems to also play a role in cancer progression
of other entities. In bone metastatic breast and prostate
cancer cells, calcium and CaSR induces proliferation and
motility [26,27]. In parathyroid cancer, CaSR expression
reduces Ki67 antigen level and therefore is inversely cor-
related with cell proliferation [28]. Also in astrocytoma
cells [29] and ovarian cells [30,31], CaSR activation in-
duced proliferation and functioned as an oncogene. In
contrast to these results, in colon carcinoma cells and
neuroblastoma cells, calcium and activation of the CaSR
have been shown to inhibit proliferation and induce
apoptosis [32,33], indicating CaSR as a tumor suppres-
sor. The impact of calcium and activation of CaSR seem
to be dependent on cell type and have to be considered
tissue specific.
The CaSR is a G-protein coupled receptor [34] activat-
ing several signaling pathways which are known to regu-
late cell proliferation, differentiation, migration and
apoptosis [35,17]. The PI3K (phospatidyl-inositol 3-
kinase)/AKT pathway, the PLCγ-1 pathway and the
MAPK (mitogen activated protein kinase) cascades are
downstream targets of the CaSR [34-36]. In our study,
calcium treatment resulted in a clearly enhanced activity
of AKT/PKB and PLCγ-1 in bone metastasizing cells but
not in non-metastasizing cells. In addition, in bone me-
tastasizing cells, calcium had an activating effect on the
MAP kinases p38α and JNK. The focal adhesion adapter
protein paxillin as well as c-Jun, both downstream targets
of JNK [37,38], showed comparable activity patterns. Inhi-
biting CaSR with NPS 2143 these enhancements were pre-
vented and the phosphorylation of the signal mediator
with the highest calcium sensitivity, AKT, was reduced.
The additional reduction of AKT activity after inhibition
of CaSR indicates a basement activity of CaSR even
without adding calcium. The culture medium contains
a low level of calcium not specified by the company.
Presumably this low calcium concentration leads to a
slightly activation of CaSR and consequently also of
AKT-phosphorylation. This effect seems to be inhibited
by NPS 2143. The reduced AKT activity induced by
NPS 2143 treatment confirms the responsibility of
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calcium had no activating effect on ERK. This suggests
AKT, PLCγ-1, p38α and JNK/paxillin signaling path-
ways, which are described as downstream targets of
CaSR [27,36,39,40], being the crucial pathways in the
CaSR signaling in RCC cells promoting bone specific
metastasis (Figure 6). However, ERK as a downstream
target of CaSR is discussed controversially [41] and
some studies hypothesize the ERK pathway being in-
volved in extracellular calcium induced cell migration
[26,30], again confirming a cell type specific function of
CaSR as already described [42]. The main regulator of
the AKT pathway is the tumor suppressor PTEN. As an
antagonist of the PI3Kinase, PTEN inhibits the activa-
tion of AKT and thereby down-regulates cell prolifera-
tion and migration [43-45]. In addition, in our former
investigations we established a correlation between low
PTEN expression in specimens of RCC patients and
poor prognosis caused by metastasis [46]. In bone me-
tastasizing RCC cells, PTEN expression was approxi-
mately 50% lower than in non-metastasizing cells. The
expression of PTEN correlated inversely with the activ-
ity of AKT. In addition, the expression of PTEN was
highly calcium sensitive. Calcium treatment resulted in
an almost complete decline in the expression of PTEN.
This implicates that the per se low PTEN expression in
bone metastasizing RCC cells is further reduced by the
bone microenvironment, consequently activating the

















Figure 6 Signaling pathways involved in the calcium dependent
bone metastasis of RCC. Results obtained in this study are marked
with an arrow: arrow upwards means enhancement, arrow
downwards means reduction. In cells obtained from patients who
developed bone metastases within 5 years after nephrectomy, the
expression and activity of CaSR, JNK, paxillin, p38α, PLCγ1 and AKT
was enhanced after calcium treatment, PTEN expression was
reduced, resulting in an enhanced migration and proliferation.Our study indicates that bone metastasis of RCC is
promoted by an enhanced expression of CaSR. Calcium
induces migration and proliferation of bone metastatic
RCC cells via CaSR and its signaling pathways and fi-
nally promotes bone metastasis. The role of CaSR as a




Tissue samples were obtained under sterile conditions
from 33 patients with primary RCC who underwent
nephrectomy at the Department of Urology, Johannes
Gutenberg University Medical Center, Mainz, Germany.
The study was performed in agreement with the Declar-
ation of Helsinki and approved by local ethics committee
(Landesärztekammer Rheinland-Pfalz, Mainz, Germany:
837.005.09, and the ethics committee of the University
Jena, Germany: 2878-07/10). Informed consent was ob-
tained from each patient. Samples from tumor tissue
and normal renal cortex, obtained from the opposite
kidney pole at a minimum of 3 cm from the tumor,
(5x5x5 mm approximately) were shock frozen in liquid
nitrogen and stored at −80°C for a period of at least
5 years. The diagnosis of RCC was based on hematoxylin
and eosin sections. The development of metastatic sites
within 5 years after nephrectomy varied: 11 non-
metastasized, 11 metastasized into the lung and 11 me-
tastasized into bones. Tumor specimens were stratified
according to histological tumor type, grading, staging,
gender, patient’s age and tumor size.
Quantitative RT–PCR for CaSR mRNA
Total RNA was isolated from renal tissue using a RNA
isolation kit (RNeasy Kit, Quiagen, Hilden, Germany).
RNA from each tissue was reverse transcribed using a
cDNA synthesis kit for RT-PCR (SuperScript II, Invitro-
gen, Karlsruhe, Germany). cDNA was amplified with a
CaSR specific forward primer, 5′-AAG AAA GTT GAG
GCG TGG CAG-3′, and a reverse primer, 5′-GAG GTC
CCA GTT GAT GAT GGA-3′ (each 10 pmol). CaSR
specific amplification was performed in a 10 μl mixture
using 5 μl of Light Cycler 480 Cyber Green I Master
(Roche) and 1 μl of the cDNA sample. Thermocycling
consisted of 50 cycles at 95°C for 5 sec, 61°C for 5 sec
and 72°C for 10 sec, followed by a final melting at 95°C.
RT-PCR of TBP (TATA-box binding protein) and β-
actin from all samples was performed simultaneously for
reference, using the arithmetic average of these house-
keeping genes.
Cells and cell culture
Primary RCC cells were isolated from tumor specimens
of patients developing bone, lung or no metastases (3 for
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ation of cells was performed in agreement with the Dec-
laration of Helsinki and approved by local ethics
committee (Landesärztekammer Rheinland-Pfalz, Mainz,
Germany: 837.005.09, and the ethics committee of the
University Jena, Germany: 2878-07/10). Tumor speci-
mens of approximately 1 cm2 were obtained from renal
tumors shortly after nephrectomy under sterile condi-
tions, separated mechanically with a scalpel and dissoci-
ated with 1 mg/ml collagenase II (Sigma, St. Louis,
USA) for 30 min at 37°C. To complete dissociation, the
samples were pressed through a 70 μm cell strainer.
After centrifugation at 1000 rpm for 10 min, the cell pel-
lets were dissolved in AmnioMAX C100 Basal Medium
including AmnioMAX C100 Supplement (Gibco, Life
Technologies, Darmstadt, Germany). Cells were incu-
bated at 37°C in a humidified atmosphere containing 5%
CO2 in air. Epithelial origin was proven by immunocyto-
chemical staining of cytokeratins. After growing to semi-
confluence, primary cells were cryo-conserved in
medium containing 10% DMSO in liquid nitrogen for at
least 5 years until usage for the analyses. Cells from pa-
tients without-, with lung- or with bone metastases (3
each) were thawed and cultured for 2- to 4- passages.
For experimental use and protein extraction, cells were
serum-starved for 24 h and treated with 5 mM calcium
for 30 min under serum-free conditions. The allosteric
CaSR inhibitor NPS 2143 (5 μM) was applied for 1 h
(first 30 min without, then 30 min together with cal-
cium). Although NPS 2143 was solved in DMSO result-
ing in a DMSO concentration in culture medium of
0.005%, we used serum free serum as a control, since we
observed an influence of DMSO from a concentration of
0.5% (data not shown).Immunocytochemistry
Immunocytochemical staining of cytokeratin pan was
performed to prove the epithelial origin of the primary
renal tumor cells. Renal tumor cells (5 × 103 cells/ml)
were centrifuged on microscope slides and fixed in 100%
ethanol for 10 min. Endogene peroxidase was blocked
by a 5 min treatment with peroxidase blocking solution
(Dako, Hamburg, Germany). Mouse anti-cytokeratin pan
monoclonal antibody (Abcam, Cambridge, UK), diluted
1:200 in antibody-diluent (LSAB + −Kit, Dako, Carpin-
teria, USA), was incubated for 1 h at room temperature.
The secondary biotinylated anti-mouse antibody (Dako)
was applied for 30 min at room temperature. After using
a horseradish peroxidase-conjugated strepatividin-label
(LSAB + −Kit, DAKO) for 30 min, cells were treated with
DAB (Diaminobenzidine, Dako) for 10 min and counter-
stained with Mayer’s Hemalm. For all experiments only
cytokeratin positive cells were used.Flow cytometry
The expression of the CaSR in renal tumor cells was
quantified by flow cytometry. Fixation of the cells (2 ×
106 cells/ml) was performed in 3.7% paraformaldehyde
for 10 min. Mouse monoclonal anti-CaSR (Sigma, St.
Louis, USA) was used in a concentration of 0.2 μg/μl,
mouse anti-human isotypic control immunglobulines
(Dako, Carpinteria, USA) were used in a concentration
of 15 μg/μl in PBS containing 1% bovine serum albumin
(BSA) for 20 min at 4°C. The secondary alexa flour 488
goat anti-mouse antibody was diluted 1:1000 in 1% BSA/
PBS and incubated for 20 min at 4°C in darkness. CaSR
expression was quantified in a flow cytometer (BD Calibur,
Becton Dickinson, Heidelberg, Germany).
Cell migration assay
For migration analysis a microchemotaxis chamber
(Boyden chamber, Costar, Cambridge, USA) containing an
upper and a lower chamber separated by a porous poly-
carbonate membrane (pore diameter 8 μm; Neuroprobe
Inc., Gaithersburg, USA) was employed. The chamber was
divided into 48 wells, resulting in an invasion unit with a
surface of approximately 7.8 mm2. The wells of the lower
part of the chamber were coated with 29 μl calcium
(10 mM) in serum-free medium or medium alone as con-
trol. The lower part was covered with the polycarbonate
membrane, previously coated with PBS. 50 μl of the tumor
cell suspension (3 × 105 cells/ml) were loaded to the upper
part of the chamber in quadruplicate. After an incubation
period of 16 h at 37°C in a humidified atmosphere con-
taining 5% CO2 in air, cells that did not pass the polycar-
bonate membrane were removed from the upper side of
the porous membrane by washing with a Weise buffer
(Merck, Darmstadt, Germany; a potassium dihydrogen
phosphate buffer, pH 7.0) and by mechanical removal with
a rubber policeman. The membrane was dried and fixed
in methanol for 1 min. Afterwards the nuclei were stained
with hemacolor (Merck), washed twice with Weise buffer
and embedded on a microscope slide coated with
immersion oil. The number of invasive tumor cells was
evaluated by a microscopic test raster ocular (Zeiss, 400-
fold magnification). For a single determination, ten differ-
ent views per well with a combined membrane surface of
2.5 mm2 were evaluated. For statistical confirmation, a
mean value and a standard error were calculated from the
results [47].
Analysis of cell proliferation
To study the effect of extracellular calcium on prolifera-
tion of primary RCC cells, a colorimetric BrdU incorpor-
ation assay (Roche, Mannheim, Germany) was performed.
The cells were seeded into a 96 well plate (5 × 103 cells/
well), cultured for 48 h and treated in quadruplicate by
distinct calcium concentrations (0 mM, 2.5 mM, 5 mM,
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effect was analyzed by pretreating the cells with NPS 2143
(5 μM) for 1 h (first 30 min without, then 30 min together
with calcium). BrdU solution (10 μM) was added to the
cells without replacing the NPS 2143 and/or calcium con-
taining culture medium and incubated for 2 h in presence
of calcium at 37°C in a humidified atmosphere containing
5% CO2 in air. The tumor cells were fixed and the DNA
was denatured in one step by adding fixDenat solution for
30 min. Incorporated BrdU was detected by an anti-BrdU-
POD antibody within 60 min. The immune complex was
detected by a subsequent substrate reaction and quantified
by measuring the absorbance at 450 nm (reference wave-
length 690 nm) [48].
Human phospho-kinase array
The activity of 46 intracellular signaling kinases was
quantified by using a human phospho-kinase array
(R&D, Minneapolis, USA). The kinase array was per-
formed in accordance with the instructions in the man-
ual. Briefly, protein extracts from primary renal tumor
cells (cultivated from patients developing no or bone
metastases) were prepared by using 200 μl lysis buffer 6
included in the kit. The cells were rinsed twice with ice-
cold PBS and scraped off with a rubber policeman in
lysis buffer. After 30 min incubation on ice, the extracts
were centrifuged at 14.000 rpm, 4°C for 10 min. Protein
concentrations were determined using BCA (bicinchoni-
nic acid) reagent (Thermo Scientific, Rockford, USA).
The phospho-kinase array membranes were incubated
with array buffer 1 for 1 h on a rocking platform. On
each membrane 1 ml of the protein lysates (300 μg) were
added and incubated overnight at 4°C on a rocking plat-
form. The membranes were washed three times with
washing buffer and shaken with antibody cocktails for
2 h. After a 30-minute treatment with streptavidin-HRP
solution, the membranes were exposed to a chemilumin-
escent reagent. Positive signals were visualized using a
Chemiluminescence-Imaging System. The amount of
protein in each spot was calculated by using Image J
software (NIH).
Western blot analysis
For preparation of protein extracts, renal tumor and
normal tissue was pulverized with a mortar under liquid
nitrogen and suspended on ice in lysis buffer (20 mM
Hepes, pH 7.7, 0.2 M NaCl, 1.5 mM MgCl2, 0.4 mM
EDTA, 1% Triton X-100, 0.5 mM DTT including prote-
ase and phosphatase inhibitors (Sigma, Steinheim,
Germany)). For preparation of protein extracts from cell
culture, the cells were rinsed twice with ice-cold
phosphate-buffered saline (PBS) and scraped off with a
rubber policeman in lysis buffer. After 30 min incuba-
tion on ice the extracts were centrifuged at 14.000 rpm,4°C for 10 min. Protein concentrations of the extracts
were determined using BCA (bicinchoninic acid) reagent
(Thermo Scientific, Rockford, USA). Equal amounts of
protein extracts (100 μg per lane) were separated by
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide) gel
electrophoresis of 10% polyacrylamide (Rotiphorese-Gel
30, Roth, Karlsruhe, Germany) and transferred onto
polyvinylidene fluoride membranes (Poly Screen PVDF
Transfer Membrane, Perkin Elmer, Rodgau, Germany)
by semi-dry blotting. The membrane was blocked in
Roti-block blocking solution (Roth, Karlsruhe, Germany)
for 1 h. The primary antibodies were incubated in block-
ing solution (tris buffered saline (TBS), 0.1% Tween 20
and 5% non-fat milk) at 4°C overnight. The antibodies
against CaSR (Sigma, Steinheim, Germany), PTEN (phos-
phatase and tensin homolog deleted on chromosome ten)
(monoclonal, rabbit, Cell Signaling), phospho-AKT
(Ser473, Thr308, Cell Signaling, Danvers, USA), phospho-
ERK (Thr202/Tyr204, Tyr185/Tyr187, Cell Signaling,
Danvers, USA) were diluted 1:1000, anti-β-actin (Sigma
Aldrich, Taufkirchen, Germany) was diluted 1:5000.
The horseradish peroxidase-conjugated secondary anti-
body (rabbit anti-mouse and goat anti-rabbit, Dako,
Hamburg, Germany) was incubated for 1 h at room
temperature. Antigens were visualized by an enhanced
chemiluminescence solution (ECL, Perkin Elmer Life
Sciences, Waltham, USA) using a Chemiluminescence-
Imaging System (Fusion-SL4.2 MP, Peqlab, Erlangen,
Germany). The amount of expressed protein was calcu-
lated analogously by computer-aided integration of the
band using Image J software (NIH, USA) after subtrac-
tion of the background and referred to the value of
total protein, quantified by Coomassie staining of the
membrane, (for tissue specimens) and β-actin (for cell
extracts), respectively [47].Statistical analysis
For statistical analyses IBM-SPSS 19.0 software and Excell
2010 was applied. CaSR mRNA expression in renal tumor
and normal tissue was quantified and presented as relative
units. All other results using primary RCC cells were pre-
sented in% of the untreated non-metastasizing cells or re-
lated to untreated cells. Differences in the expression of
CaSR, cell migration and proliferation were performed
using the Student’s T-test. Differences were considered
statistically significant at p < 0.05.
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